An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC

INTRODUCTION: SCLC is a highly aggressive tumor with a 5-year survival rate of less than 6%. A heterogeneous disease, SCLC is classified into four subtypes that include tumors with neuroendocrine and non-neuroendocrine features. Immune checkpoint blockade therapy has been recently added for the fron...

Descripción completa

Detalles Bibliográficos
Autores principales: Fousek, Kristen, Horn, Lucas A., Qin, Haiyan, Dahut, Madeline, Iida, Masafumi, Yacubovich, Dan, Hamilton, Duane H., Thomas, Anish, Schlom, Jeffrey, Palena, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974560/
https://www.ncbi.nlm.nih.gov/pubmed/36410696
http://dx.doi.org/10.1016/j.jtho.2022.11.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974560/
https://www.ncbi.nlm.nih.gov/pubmed/36410696
http://dx.doi.org/10.1016/j.jtho.2022.11.008

Ejemplares similares